Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences-Reference-Cited by-同舟云学术

Willingness to pay for a quality-adjusted life year: an evaluation of attitudes towards risk and preferences

Published:2014-07-03 Issue:1 Volume:14 Page:
ISSN:1472-6963
Container-title:BMC Health Services Research
language:en
Short-container-title:BMC Health Serv Res

Author:

Martín-Fernández Jesus,Polentinos-Castro Elena,del Cura-González Ma Isabel,Ariza-Cardiel Gloria,Abraira Victor,Gil-LaCruz Ana Isabel,García-Pérez Sonia

Publisher

Springer Science and Business Media LLC

Subject

Health Policy

Link

http://link.springer.com/content/pdf/10.1186/1472-6963-14-287.pdf

Reference41 articles.

1. Reidpath DD, Olafsdottir AE, Pokhrel S, Allotey P: The fallacy of the equity-efficiency trade off: rethinking the efficient health system. BMC Public Health. 2012, 12 (Suppl 1): S3.

2. Bobinac A, van Exel NJ, Rutten FF, Brouwer WB: GET MORE, PAY MORE? An elaborate test of construct validity of willingness to pay per QALY estimates obtained through contingent valuation. J Health Econ. 2012, 31: 158-168.

3. Weinstein MC, Torrance G, McGuire A: QALYs: the basics. Value Health. 2009, 12 (Suppl 1): S5-S9.

4. Baker R, Chilton S, Donaldson C, Jones-Lee M, Lancsar E, Mason H, Metcalf H, Pennington M, Wildman J: Searchers vs surveyors in estimating the monetary value of a QALY: resolving a nasty dilemma for NICE. Health Econ Policy Law. 2011, 6: 435-447.

5. Culyer A, McCabe C, Briggs A, Claxton K, Buxton M, Akehurst R, Sculpher M, Brazier J: Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical excellence. J Health Serv Res Policy. 2007, 12: 56-58.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acne scars impact on the quality of life and the willingness to pay for treatments among adults in Riyadh, Saudi Arabia: A cross-sectional study;Journal of Cutaneous and Aesthetic Surgery;2024-08-29

2. International Cost-Effectiveness Analysis of Durvalumab in Stage III Non–Small Cell Lung Cancer;JAMA Network Open;2024-05-30

3. Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis;2024-02-28

4. Do carbon labels increase Chinese consumers’ willingness to pay for carbon-labeled agricultural products?;Journal of Cleaner Production;2024-01

5. Optimal assessment share structured of Pharmacoeconomics for medical drugs according to minimax criterion;PHARM PRACT-GRANADA;2024